He Jia-Qi, Zheng Min-Xia, Ying Hua-Zhong, Zhong Yu-Sen, Zhang Huan-Huan, Xu Min, Yu Chen-Huan
The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China.
The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China.
Int J Biol Macromol. 2020 May 4;158:542-551. doi: 10.1016/j.ijbiomac.2020.04.193.
Two polysaccharides (PRP1 and PRP2) were isolated from Platycodonis Radix. Preliminary structural analysis indicated that PRP1 was composed of glucose, fructose, and arabinose in a molar ratio of 1:1.91:1.59 with a molecular weight of 440 kDa, whereas PRP2 was composed of arabinose, fructose, and galactose in a molar ratio of 1:1.39:1.18 with a molecular weight of 2.85 kDa. Compared with PRP2, PRP1 exerted stronger anticancer activity in vitro. Treatment with 5-30 μg/ml of PRP1 significantly inhibited the proliferation of HepG2 cells in vitro, and oral administration at the doses of 75-300 mg/kg also reduced the tumor growth in vivo. The miRNA expression patterns of human liver cancer cells HepG2 in vivo under PRP1 treatment were established, and microRNA-21 (miR-21) as the onco-miRNA was appreciably downregulated. PRP1 repressed the expression of miR-21, which directly targeted and suppressed PTEN (a negative regulator of the PI3K/Akt signaling cascade), and subsequently upregulated the expression of PTEN but downregulated the PI3K/AKT pathway, thereby promoting liver cancer cell apoptosis. These findings indicated that PRP1 inhibited the proliferation and induced the apoptosis of HepG2 mainly via inactivating the miR-21/PI3K/AKT pathway. Therefore, PRP1 could be used as a food supplement and candidate for the treatment of liver cancer.
从桔梗中分离出两种多糖(PRP1和PRP2)。初步结构分析表明,PRP1由葡萄糖、果糖和阿拉伯糖组成,摩尔比为1:1.91:1.59,分子量为440 kDa,而PRP2由阿拉伯糖、果糖和半乳糖组成,摩尔比为1:1.39:1.18,分子量为2.85 kDa。与PRP2相比,PRP1在体外具有更强的抗癌活性。用5 - 30 μg/ml的PRP1处理可显著抑制体外HepG2细胞的增殖,以75 - 300 mg/kg的剂量口服给药也可减少体内肿瘤生长。建立了PRP1处理下体内人肝癌细胞HepG2的miRNA表达模式,作为癌基因miRNA的microRNA - 21(miR - 21)明显下调。PRP1抑制miR - 21的表达,miR - 21直接靶向并抑制PTEN(PI3K/Akt信号级联的负调节因子),随后上调PTEN的表达但下调PI3K/AKT途径,从而促进肝癌细胞凋亡。这些发现表明,PRP1主要通过使miR - 21/PI3K/AKT途径失活来抑制HepG2的增殖并诱导其凋亡。因此,PRP1可作为一种食品补充剂和肝癌治疗的候选药物。